I see the future and the future is bright indeed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ISOLF
Isodiol Is A Running Bull That Continues To See Green
13 min 54 sec ago
While Canadian licensed medical marijuana producers remain in the limelight, we have focused on several Canadian firms that are not involved in the cultivation or sale of marijuana.
We remain bullish on Canadian licensed medical marijuana producers, but believe there are several attractive long-term opportunities not focused on this side of the market.
One company that falls under this category is Isodiol International Inc. (ISOL.CN) (ISOLF) and we are bullish on its long-term growth prospects. The company continues to see significant demand for its cannabis consumer products and we are favorable on the company for the following reasons:
Continues to record strong revenue growth,
Entered a partnership with Canopy Growth (WEED.TO),
Continues to enter and focus on new international markets,
Its balance sheet is flush with cash and will support growth initiatives.
Completes $25 Million Financing
Today, Isodiol significantly strengthened its balance sheet after it signed a convertible debenture financing for $25,000,000 CDN with Alumnia Partners. The company plans to use the proceeds to further expand its global reach and to execute on strategic acquisitions. Isodiol continues to focus on innovation and the development of valuable intellectual property. This capital will support these initiatives.
The debenture has no minimum draw down requirement, a two-year term, and an 8% interest rate. The conversion terms associated with the debenture consist of one common share and one half of one common share purchase warrant at discounts ranging from 15% to 25% of the market price of the shares. The exercise price of the warrants will be at a 50% premium over the market price of the shares.
New Opportunities to Support Above-Average Growth
The last quarter has been significant for Isodiol and we expect these developments to benefit the company over the coming quarters.
In July, Canopy Growth and Isodiol signed a licensing agreement where Canopy can manufacture and distribute Pot-O-Coffee and Pot-O-Tea branded marijuana infused single serve K-Cup products in Canada and international markets that allow it.
We are favorable on this partnership and expect it to pay dividends for Isodiol. Through Tweed Main Street, Canopy Growth services more than 58,000 registered patients and this outlet has proven to be a great revenue stream for companies such as Isodiol.
Continues to Increase Market Share and Enter New Markets
Isodiol continues to expand its reach and has successfully entered new markets. We are favorable on these developments and expect the company to enter several new markets over the next year.
One of the exciting developments in this area for Isodiol took place during June when the company started the approval process through Brazil’s Health Regulatory Agency to have its CBD products added to the list of approved imported CBD products.
We are favorable on the Brazil market and believe that the company can gain significant traction within it. Shortly after this announcement, Isodiol reported to have established operations in Mexico and said that it would start shipping its CBD products throughout the country.
Executing on All Cylinders
Last month, Isodiol provided an operational update on its subsidiary, Iso International and the results exceeded our expectations. During the period, Iso recorded a net profit of almost $897,596 on $4,919,693 in revenue. Although these numbers are un-audited, we expect the company to report operating results that are in line with these numbers.
This development is significant for Isodiol and represents a milestone for the company. Isodiol has continued to execute on its business plan and specializes in the development of pharmaceutical and consumer products.
We are favorable on Isodiol's multi-faceted growth strategy and expect to see continued growth for quarters to come. The company will benefit from a diverse strategy that is focused on both organic and inorganic growth opportunities.
No worries mate, all good. Thanks for posting.
$ISOLF www.isodiol.com
Great update, as you can see $ISOLF is really trying to move into the Brazilian CBD market which could be massive for this company in the near future IMHO.
VANCOUVER, Aug. 9, 2017 /CNW/ - Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (Frankfurt: LB6A.F) (the "Company" or "Isodiol") a global cannabis innovator specializing in the development of pharmaceutical and consumer products announces it is proudly sponsoring the 50th Anniversary of IV International and XXIV Brazilian Congress of ABENEPI (Brazilian Association of Neurology and Child Psychiatry and Related Profession) August 9 – 12. The Company is sponsoring the symposium where one of the top Brazilian child neurologists will be speaking on the benefits of Cannabidiol to an audience of doctors, neurologists and psychologists.
Marcos Agramont CEO of Isodiol stated, "As we develop our footprint in Brazil and work through the process with Anvisa, sponsoring events like this will be very important for educating the market on the benefits of our Isoderm™ product. Over the last several months, we have been able to generate tremendous support for our products which we anticipate will continue as we move into additional countries."
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
"Marcos Agramont"
CEO & Director
Join Us On Face Book:
https://www.facebook.com/isodiol/
Twitter: @isodiol
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=26559780#zIJrSBtIStfEgZVq.99
Hey Clay, I thought that you might find this company interesting $ISOLF one of a few companies in the sector making great revenue, plus profitable. Its starting to get a lot of traction up in Canada and the U.S symbol has started to trade decent volume. Cheers
$ISOLF
www.isodiol.com
$ISOLF
www.isodiol.com
No problem, this is one of a very few companies within the sector that is actually profitable. Last months revenues we're over $1.35 Million U.S.
Here's the website www.isodiol.com $ISOLF
Expecting a great week ahead for $ISOLF
Isodiol Report Stellar Sales Numbers With Zero Signs Of Slowing Down
August 2, 2017
The global cannabis industry continues to expand and this has created new opportunities for companies levered to this opportunity.
Over the last two years, we have learned a lot about the cannabis plant and the medical benefits associated with marijuana. During this time, a chemical compound found in the plant, Cannabidiol (CBD) has become one of the best known chemical compounds and this is primarily due to its medical benefits.
Isodiol: Capitalizing on Demand for Cannabis Products
Isodiol International Inc. (ISOL.CN) (LAGBF) is one of the companies capitalizing on this burgeoning opportunity, however, the company has recently come under pressure.
Last week, the company provided an operational update on its subsidiary, Iso International and the results were strong. During the quarter, Iso recorded a net profit of almost $897,596 on $4,919,693 in revenue. Although these numbers are un-audited, we expect the company report operating results that are in line with these numbers.
This development is significant for Isodiol and represents a milestone for the company. We have been monitoring Isodiol closely and the company has been laser focused on increasing market share and entering new international markets.
Isodiol CEO Marcos Agramont said the company is positioned to begin exploring additional expansion opportunities and is specifically focused on vertical integration, expanding its product distribution channels, and out-of-state manufacturing and processing.
A Multi-Faceted Growth Strategy
Isodiol has continued to execute on its business plan and specializes in the development of pharmaceutical and consumer products. The company’s nutraceutical division has been focused on developing hemp-derived cannabidiol (CBD) for the highest quality consumable and topical skin care products.
We are favorable on Isodiol's multi-faceted growth strategy and expect to see continued growth for quarters to come. The company will benefit from a diverse strategy that is focused on both organic and inorganic growth opportunities.
Part of its strategy includes developing over-the-counter and pharmaceutical drugs, entering joint venture partnerships and making acquisitions to expand its portfolio of brands and subsidiaries, and continuing to expand internationally and enter new markets in Latin America, Asia and Europe.
New Distribution and Growth Opportunities
The last two months have been very significant for Isodiol and we expect these developments to benefit the company over the coming quarters.
In July, Canopy Growth (WEED.TO) (TWMJF) and Isodiol announced a licensing agreement where Canopy can manufacture and distribute Pot-O-Coffee and Pot-O-Tea branded marijuana infused single serve K-Cup products in Canada and international markets that allow it. Canopy also has the right of first refusal to sell Pot-O branded products in any territory outside of the United States, Mexico and Puerto Rico.
This development took place only one month after Isodiol acquired the cannabis-based beverage company for 20,937,500 common shares (at $0.12 a share) and a one-time cash payment of $250,000.
Isodiol continues to expand its reach and has successfully entered new markets. We are favorable on these developments and expect the company to enter several new markets over the next year.
One of the exciting developments in this area for Isodiol took place during June when the company started the approval process through Brazil’s Health Regulatory Agency to have its CBD products added to the list of approved imported CBD products.
We are favorable on the Brazil market and believe that the company can gain significant traction within it. Shortly after this announcement, Isodiol reported to have established operations in Mexico and said that it would start shipping its CBD products throughout the country.
Well Capitalized and Positioned to Execute
Isodiol is well capitalized and this will help the company execute on new market opportunities. During June, Isodiol closed the second tranche of its non-brokered private placement for $1,896,954 in gross proceeds.
The private placement was oversubscribed and generated more than $4.1 million in proceeds. The company sold units at $0.12 and each unit was comprised of one common share and one common share purchase warrant (exercisable at $0.25 for a period of two years).
Isodiol said that it plans to use the proceeds primarily for working capital and general corporate purposes, which may include expansion of growth, research and development.
An Attractive Global Growth Story
Although Isodiol has continued to execute, the shares have come well off its recent highs and we are monitoring how the shares trade off these levels. The company’s products continue to gain traction and we expect to see continued growth.
We are favorable on the un-audited quarterly results, the partnership with Canopy Growth, the continued focus on new international markets, the stronger balance sheet, and the growth prospects.
Stay up to date on the GreenRush by subscribing to Technical420…
Another stellar month for $ISOLF +Talks of Worldwide Expansion for those of you who missed this AM's News Release.
Isodiol International Inc. has released unaudited July, 2017, revenue numbers of its wholly owned subsidiary ISO International LLC of $1,358,787 (U.S.).
Marcos Agramont, chief executive officer of Isodiol, stated: "We have demonstrated another strong month of top-line revenues in what typically is a slow period of the year. Our sales and marketing teams have done an incredible job developing distributor and customer relationships which provide the company with reoccurring monthly business. In an ultracompetitive industry that is continuously evolving, we continue to establish ourselves as leaders in product quality and service. The company continues to develop and gain penetration with its pharmaceutical-grade products in Latin America and remains committed to increasing its top-line revenues and ultimately increasing its profitability. We continue to develop our infrastructure in Latin America and will begin the due diligence process of expanding into the European and Asian markets in the near future."
About Isodiol International Inc. $ISOLF
Isodiol International is the market leader in pharmaceutical-grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for hemp-derived cannabinoids, including 99-per-cent-pure crystalline isolate, microencapsulation, and nanotechnology for the highest-quality consumable and topical skin care products
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=26546739#YiLBpVi4P9ktKEFa.99
$ISOLF just put out more news showing great revenue numbers for the company plus they are talking about possible expansion into Europe and Asia.
ISODIOL INTERNATIONAL INC. JULY 2017 CORPORATE UPDATE $ISOLF
Isodiol International Inc. has released unaudited July, 2017, revenue numbers of its wholly owned subsidiary ISO International LLC of $1,358,787 (U.S.).
Marcos Agramont, chief executive officer of Isodiol, stated: "We have demonstrated another strong month of top-line revenues in what typically is a slow period of the year. Our sales and marketing teams have done an incredible job developing distributor and customer relationships which provide the company with reoccurring monthly business. In an ultracompetitive industry that is continuously evolving, we continue to establish ourselves as leaders in product quality and service. The company continues to develop and gain penetration with its pharmaceutical-grade products in Latin America and remains committed to increasing its top-line revenues and ultimately increasing its profitability. We continue to develop our infrastructure in Latin America and will begin the due diligence process of expanding into the European and Asian markets in the near future."
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for hemp-derived cannabinoids, including 99-per-cent-pure crystalline isolate, microencapsulation, and nanotechnology for the highest-quality consumable and topical skin care products.
Good morning Pistol Pete, just wanted to let you know that $LAGBF has changed its trading symbol to $ISOLF. Plus they just put more news out on great revenue and are talking about possible expansion into Asia and Europe which would mean even more revenue for the company.
ISODIOL INTERNATIONAL INC. JULY 2017 CORPORATE UPDATE $ISOLF
Isodiol International Inc. has released unaudited July, 2017, revenue numbers of its wholly owned subsidiary ISO International LLC of $1,358,787 (U.S.).
Marcos Agramont, chief executive officer of Isodiol, stated: "We have demonstrated another strong month of top-line revenues in what typically is a slow period of the year. Our sales and marketing teams have done an incredible job developing distributor and customer relationships which provide the company with reoccurring monthly business. In an ultracompetitive industry that is continuously evolving, we continue to establish ourselves as leaders in product quality and service. The company continues to develop and gain penetration with its pharmaceutical-grade products in Latin America and remains committed to increasing its top-line revenues and ultimately increasing its profitability. We continue to develop our infrastructure in Latin America and will begin the due diligence process of expanding into the European and Asian markets in the near future."
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for hemp-derived cannabinoids, including 99-per-cent-pure crystalline isolate, microencapsulation, and nanotechnology for the highest-quality consumable and topical skin care products.
Another stellar month for $ISOLF, plus they are talking about possible expansion into Europe and Asia.
ISODIOL INTERNATIONAL INC. JULY 2017 CORPORATE UPDATE
Isodiol International Inc. has released unaudited July, 2017, revenue numbers of its wholly owned subsidiary ISO International LLC of $1,358,787 (U.S.).
Marcos Agramont, chief executive officer of Isodiol, stated: "We have demonstrated another strong month of top-line revenues in what typically is a slow period of the year. Our sales and marketing teams have done an incredible job developing distributor and customer relationships which provide the company with reoccurring monthly business. In an ultracompetitive industry that is continuously evolving, we continue to establish ourselves as leaders in product quality and service. The company continues to develop and gain penetration with its pharmaceutical-grade products in Latin America and remains committed to increasing its top-line revenues and ultimately increasing its profitability. We continue to develop our infrastructure in Latin America and will begin the due diligence process of expanding into the European and Asian markets in the near future."
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for hemp-derived cannabinoids, including 99-per-cent-pure crystalline isolate, microencapsulation, and nanotechnology for the highest-quality consumable and topical skin care products.
$ISOLF
Isodiol Report Stellar Sales Numbers With Zero Signs Of Slowing Down
August 2, 2017
The global cannabis industry continues to expand and this has created new opportunities for companies levered to this opportunity.
Over the last two years, we have learned a lot about the cannabis plant and the medical benefits associated with marijuana. During this time, a chemical compound found in the plant, Cannabidiol (CBD) has become one of the best known chemical compounds and this is primarily due to its medical benefits.
Isodiol: Capitalizing on Demand for Cannabis Products
Isodiol International Inc. (ISOL.CN) (LAGBF) is one of the companies capitalizing on this burgeoning opportunity, however, the company has recently come under pressure.
Last week, the company provided an operational update on its subsidiary, Iso International and the results were strong. During the quarter, Iso recorded a net profit of almost $897,596 on $4,919,693 in revenue. Although these numbers are un-audited, we expect the company report operating results that are in line with these numbers.
This development is significant for Isodiol and represents a milestone for the company. We have been monitoring Isodiol closely and the company has been laser focused on increasing market share and entering new international markets.
Isodiol CEO Marcos Agramont said the company is positioned to begin exploring additional expansion opportunities and is specifically focused on vertical integration, expanding its product distribution channels, and out-of-state manufacturing and processing.
A Multi-Faceted Growth Strategy
Isodiol has continued to execute on its business plan and specializes in the development of pharmaceutical and consumer products. The company’s nutraceutical division has been focused on developing hemp-derived cannabidiol (CBD) for the highest quality consumable and topical skin care products.
We are favorable on Isodiol's multi-faceted growth strategy and expect to see continued growth for quarters to come. The company will benefit from a diverse strategy that is focused on both organic and inorganic growth opportunities.
Part of its strategy includes developing over-the-counter and pharmaceutical drugs, entering joint venture partnerships and making acquisitions to expand its portfolio of brands and subsidiaries, and continuing to expand internationally and enter new markets in Latin America, Asia and Europe.
New Distribution and Growth Opportunities
The last two months have been very significant for Isodiol and we expect these developments to benefit the company over the coming quarters.
In July, Canopy Growth (WEED.TO) (TWMJF) and Isodiol announced a licensing agreement where Canopy can manufacture and distribute Pot-O-Coffee and Pot-O-Tea branded marijuana infused single serve K-Cup products in Canada and international markets that allow it. Canopy also has the right of first refusal to sell Pot-O branded products in any territory outside of the United States, Mexico and Puerto Rico.
This development took place only one month after Isodiol acquired the cannabis-based beverage company for 20,937,500 common shares (at $0.12 a share) and a one-time cash payment of $250,000.
Isodiol continues to expand its reach and has successfully entered new markets. We are favorable on these developments and expect the company to enter several new markets over the next year.
One of the exciting developments in this area for Isodiol took place during June when the company started the approval process through Brazil’s Health Regulatory Agency to have its CBD products added to the list of approved imported CBD products.
We are favorable on the Brazil market and believe that the company can gain significant traction within it. Shortly after this announcement, Isodiol reported to have established operations in Mexico and said that it would start shipping its CBD products throughout the country.
Well Capitalized and Positioned to Execute
Isodiol is well capitalized and this will help the company execute on new market opportunities. During June, Isodiol closed the second tranche of its non-brokered private placement for $1,896,954 in gross proceeds.
The private placement was oversubscribed and generated more than $4.1 million in proceeds. The company sold units at $0.12 and each unit was comprised of one common share and one common share purchase warrant (exercisable at $0.25 for a period of two years).
Isodiol said that it plans to use the proceeds primarily for working capital and general corporate purposes, which may include expansion of growth, research and development.
An Attractive Global Growth Story
Although Isodiol has continued to execute, the shares have come well off its recent highs and we are monitoring how the shares trade off these levels. The company’s products continue to gain traction and we expect to see continued growth.
We are favorable on the un-audited quarterly results, the partnership with Canopy Growth, the continued focus on new international markets, the stronger balance sheet, and the growth prospects.
Stay up to date on the GreenRush by subscribing to Technical420…
Isodiol Report Stellar Sales Numbers With Zero Signs Of Slowing Down
23 min 17 sec ago
The global cannabis industry continues to expand and this has created new opportunities for companies levered to this opportunity.
Over the last two years, we have learned a lot about the cannabis plant and the medical benefits associated with marijuana. During this time, a chemical compound found in the plant, Cannabidiol (CBD) has become one of the best known chemical compounds and this is primarily due to its medical benefits.
Isodiol: Capitalizing on Demand for Cannabis Products
Isodiol International Inc. (ISOL.CN) (LAGBF) is one of the companies capitalizing on this burgeoning opportunity, however, the company has recently come under pressure.
Last week, the company provided an operational update on its subsidiary, Iso International and the results were strong. During the quarter, Iso recorded a net profit of almost $897,596 on $4,919,693 in revenue. Although these numbers are un-audited, we expect the company report operating results that are in line with these numbers.
This development is significant for Isodiol and represents a milestone for the company. We have been monitoring Isodiol closely and the company has been laser focused on increasing market share and entering new international markets.
Isodiol CEO Marcos Agramont said the company is positioned to begin exploring additional expansion opportunities and is specifically focused on vertical integration, expanding its product distribution channels, and out-of-state manufacturing and processing.
A Multi-Faceted Growth Strategy
Isodiol has continued to execute on its business plan and specializes in the development of pharmaceutical and consumer products. The company’s nutraceutical division has been focused on developing hemp-derived cannabidiol (CBD) for the highest quality consumable and topical skin care products.
We are favorable on Isodiol's multi-faceted growth strategy and expect to see continued growth for quarters to come. The company will benefit from a diverse strategy that is focused on both organic and inorganic growth opportunities.
Part of its strategy includes developing over-the-counter and pharmaceutical drugs, entering joint venture partnerships and making acquisitions to expand its portfolio of brands and subsidiaries, and continuing to expand internationally and enter new markets in Latin America, Asia and Europe.
New Distribution and Growth Opportunities
The last two months have been very significant for Isodiol and we expect these developments to benefit the company over the coming quarters.
In July, Canopy Growth (WEED.TO) (TWMJF) and Isodiol announced a licensing agreement where Canopy can manufacture and distribute Pot-O-Coffee and Pot-O-Tea branded marijuana infused single serve K-Cup products in Canada and international markets that allow it. Canopy also has the right of first refusal to sell Pot-O branded products in any territory outside of the United States, Mexico and Puerto Rico.
This development took place only one month after Isodiol acquired the cannabis-based beverage company for 20,937,500 common shares (at $0.12 a share) and a one-time cash payment of $250,000.
Isodiol continues to expand its reach and has successfully entered new markets. We are favorable on these developments and expect the company to enter several new markets over the next year.
One of the exciting developments in this area for Isodiol took place during June when the company started the approval process through Brazil’s Health Regulatory Agency to have its CBD products added to the list of approved imported CBD products.
We are favorable on the Brazil market and believe that the company can gain significant traction within it. Shortly after this announcement, Isodiol reported to have established operations in Mexico and said that it would start shipping its CBD products throughout the country.
Well Capitalized and Positioned to Execute
Isodiol is well capitalized and this will help the company execute on new market opportunities. During June, Isodiol closed the second tranche of its non-brokered private placement for $1,896,954 in gross proceeds.
The private placement was oversubscribed and generated more than $4.1 million in proceeds. The company sold units at $0.12 and each unit was comprised of one common share and one common share purchase warrant (exercisable at $0.25 for a period of two years).
Isodiol said that it plans to use the proceeds primarily for working capital and general corporate purposes, which may include expansion of growth, research and development.
An Attractive Global Growth Story
Although Isodiol has continued to execute, the shares have come well off its recent highs and we are monitoring how the shares trade off these levels. The company’s products continue to gain traction and we expect to see continued growth.
We are favorable on the un-audited quarterly results, the partnership with Canopy Growth, the continued focus on new international markets, the stronger balance sheet, and the growth prospects.
Stay up to date on the GreenRush by subscribing to Technical420
$LAGBF the world's highest quality CBD. Great video.
The Cannabis Market That Could Grow 700% By 2020
$LAGBF
Debra Borchardt , CONTRIBUTOR
I write about retail and cannabis.
Opinions expressed by Forbes Contributors are their own.
Cannabidiol vapor products are displayed during the Cannabis World Congress & Business Expo at the Jacob Javits Center on June 17, 2016 in New York City. (Justin Sullivan/Getty Images)
Cannabidiol (CBD) is the part of the cannabis plant that doesn't get you “high” like the THC side of the plant. It is typically used for health reasons instead of for recreational purposes. The CBD products are either derived from industrial hemp plants or marijuana plants.
The Hemp Business Journal estimated that the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. That's a 700% increase from 2016. In 2015, the market for consumer sales of hemp-derived CBD products was $90 million, plus another $112 million in marijuana-derived CBD products which were sold through dispensaries – bringing a total CBD market to $202 million last year.
Matt Karnes of Greenwave Advisors is even more optimistic about the growth of the CBD market saying, “In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow CBD only -- this is in addition to the 28 states plus DC that have legalized medical marijuana.”
There is also evidence that traditional marijuana users are willing to give CBD a try. Outco, the largest licensed cultivator in Southern California learned that 38% of users and non-users said they wanted to learn more about CBD oil. They too believe that the market is poised for growth.
Here's a graph showing $LAGBF in comparison to its market peers.
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
Check out this link on $LAGBF compared to the competition.
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
Here's a Graph showing $LAGBF in comparison to its market Peers.
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
Hi Alan, I thought that you might find this video interesting with the head doctor from Isodiol explaining the quality of their product compared to the competition.
This is just getting started guys here's a link to $LAGBF compared to the competition, it will blow your mind. $LAGBF
https://pbs.twimg.com/media/DFvLvWsWAAAeuZC.jpg
Pistol Pete, here's a list of all the Largest Licensed Producers and $LAGBF in comparison. Check out this link it will blow your mind, just to how undervalued $LAGBF is compared to the Competition.
https://pbs.twimg.com/media/DFvLvWsWAAAeuZC.jpg
This is just getting started guys here's a link to $LAGBF compared to the competition, it will blow your mind.
https://pbs.twimg.com/media/DFvLvWsWAAAeuZC.jpg
This is a list of current Marijuana companies and as you can see ISOL is doing pretty much the same Revenue as ACB but with much better Margins.
image:
https://pbs.twimg.com/media/DFvLvWsWAAAeuZC.jpg
$LAGBF
Canopy Growth Corp Gets a Bigger Taste of the Edibles Market, Raises $25 Million
Posted By Sean Mason -July 24, 2017
Share on FacebookTweet on Twitter
inShare
Share on Linkedin
SAVE ARTICLE
Agreement with Isodiol International further expands the product diversification strategy for Canopy Growth and prepares it in advance for a potential future recreational market
SmallCapPower | July 24, 2017: Canopy Growth Corporation (TSX: WEED) announced recently that it has inked a licensing agreement with Isodiol International Inc. (CSE: ISOL) for the manufacture and distribution of Isodiol’s marijuana-infused “Pot-O-Coffee” and “Pot-O-Tea” branded products in Canada and internationally. Although marijuana-infused edible products are not currently legal in Canada, the passing of Bill C-45 in April 2017 to legalize marijuana for recreational use on or before July 1, 2018 could present a large opportunity for Canopy Growth. Internationally too, only a few countries in South America (Uruguay) and Africa, and some states in the U.S. have legalized recreational use of cannabis.
For Our Complete Coverage Of Canadian Marijuana Stocks Click Here
An early entrant into the Canadian cannabis market, Canopy Growth manufactures and distributes dried, oil and softgel cannabis products under diverse brands (Tweed, Mettrum, etc) for medical uses. These brands will evolve towards an adult lifestyle brand to best serve the needs of the future adult recreational market in Canada. The agreement with Isodiol further expands its product diversification strategy and prepares it in advance for a potential future recreational market that would allow edible and drinkable consumer products infused with cannabis elements.
Isodiol’s CEO Marcos Agramont said, “This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world. We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence.”
Win Big With Our Small Cap Picks
Your email address
GET IT NOW
Canopy Growth also announced that it will raise $25 million in an equity financing private placement at $8.05 per share. The proceeds will be used to expand the production capacity of Canopy Growth, both domestically and potentially internationally, according to the Company.
For fiscal year 2017, Canopy Growth generated revenues of ~$40 million selling 5,140 kilograms of cannabis, and reported net loss of $16.6 million, or $0.14 per diluted share. At the current market price of $8.25, the market capitalization of Canopy Growth translates into $1.4 billion, or 35x its annual sales.
$LAGBF
Canopy Growth Corp Gets a Bigger Taste of the Edibles Market, Raises $25 Million
Posted By Sean Mason -July 24, 2017
Share on FacebookTweet on Twitter
inShare
Share on Linkedin
SAVE ARTICLE
Agreement with Isodiol International further expands the product diversification strategy for Canopy Growth and prepares it in advance for a potential future recreational market
SmallCapPower | July 24, 2017: Canopy Growth Corporation (TSX: WEED) announced recently that it has inked a licensing agreement with Isodiol International Inc. (CSE: ISOL) for the manufacture and distribution of Isodiol’s marijuana-infused “Pot-O-Coffee” and “Pot-O-Tea” branded products in Canada and internationally. Although marijuana-infused edible products are not currently legal in Canada, the passing of Bill C-45 in April 2017 to legalize marijuana for recreational use on or before July 1, 2018 could present a large opportunity for Canopy Growth. Internationally too, only a few countries in South America (Uruguay) and Africa, and some states in the U.S. have legalized recreational use of cannabis.
For Our Complete Coverage Of Canadian Marijuana Stocks Click Here
An early entrant into the Canadian cannabis market, Canopy Growth manufactures and distributes dried, oil and softgel cannabis products under diverse brands (Tweed, Mettrum, etc) for medical uses. These brands will evolve towards an adult lifestyle brand to best serve the needs of the future adult recreational market in Canada. The agreement with Isodiol further expands its product diversification strategy and prepares it in advance for a potential future recreational market that would allow edible and drinkable consumer products infused with cannabis elements.
Isodiol’s CEO Marcos Agramont said, “This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world. We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence.”
Win Big With Our Small Cap Picks
Your email address
GET IT NOW
Canopy Growth also announced that it will raise $25 million in an equity financing private placement at $8.05 per share. The proceeds will be used to expand the production capacity of Canopy Growth, both domestically and potentially internationally, according to the Company.
For fiscal year 2017, Canopy Growth generated revenues of ~$40 million selling 5,140 kilograms of cannabis, and reported net loss of $16.6 million, or $0.14 per diluted share. At the current market price of $8.25, the market capitalization of Canopy Growth translates into $1.4 billion, or 35x its annual sales.
$LAGBF
Canopy Growth Corp Gets a Bigger Taste of the Edibles Market, Raises $25 Million
Posted By Sean Mason -July 24, 2017
Share on FacebookTweet on Twitter
inShare
Share on Linkedin
SAVE ARTICLE
Agreement with Isodiol International further expands the product diversification strategy for Canopy Growth and prepares it in advance for a potential future recreational market
SmallCapPower | July 24, 2017: Canopy Growth Corporation (TSX: WEED) announced recently that it has inked a licensing agreement with Isodiol International Inc. (CSE: ISOL) for the manufacture and distribution of Isodiol’s marijuana-infused “Pot-O-Coffee” and “Pot-O-Tea” branded products in Canada and internationally. Although marijuana-infused edible products are not currently legal in Canada, the passing of Bill C-45 in April 2017 to legalize marijuana for recreational use on or before July 1, 2018 could present a large opportunity for Canopy Growth. Internationally too, only a few countries in South America (Uruguay) and Africa, and some states in the U.S. have legalized recreational use of cannabis.
For Our Complete Coverage Of Canadian Marijuana Stocks Click Here
An early entrant into the Canadian cannabis market, Canopy Growth manufactures and distributes dried, oil and softgel cannabis products under diverse brands (Tweed, Mettrum, etc) for medical uses. These brands will evolve towards an adult lifestyle brand to best serve the needs of the future adult recreational market in Canada. The agreement with Isodiol further expands its product diversification strategy and prepares it in advance for a potential future recreational market that would allow edible and drinkable consumer products infused with cannabis elements.
Isodiol’s CEO Marcos Agramont said, “This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world. We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence.”
Win Big With Our Small Cap Picks
Your email address
GET IT NOW
Canopy Growth also announced that it will raise $25 million in an equity financing private placement at $8.05 per share. The proceeds will be used to expand the production capacity of Canopy Growth, both domestically and potentially internationally, according to the Company.
For fiscal year 2017, Canopy Growth generated revenues of ~$40 million selling 5,140 kilograms of cannabis, and reported net loss of $16.6 million, or $0.14 per diluted share. At the current market price of $8.25, the market capitalization of Canopy Growth translates into $1.4 billion, or 35x its annual sales.
Agreed this is absolute insanity that there are only 23 followers here, but I have a feeling that's about to change.
Smart buy brother, this is one of only a handful of companies that are currently doing revenue plus profit to boot.
$LAGBF is one of the only companies in the Marijuana Sector that is Profitable.
We have developed product lines and brands which will generate revenues and profitability and now we're positioned to begin exploring additional expansion opportunities. Vertical integration, expanding product distribution channels, and out-of-state manufacturing and processing are all opportunities we will aggressively develop and execute."
ISODIOL INTERNATIONAL INC. ANNOUNCES UNAUDITED QUARTERLY PROFIT OF ISO INTERNATIONAL LLC
Isodiol International Inc. has released the operational numbers of its wholly owned subsidiary for the period from April 1, 2017, to June 30, 2017. ISO International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of $4,919,693.
Marcos Agramont, chief executive officer of Isodiol, stated: "Demonstrating Q1 profitability is a major milestone for our company and our investors. The cannabis industry on a whole will be legitimized by demonstrating successful commercialization and operating in an environment which promotes the cannabis movement. We have developed product lines and brands which will generate revenues and profitability and now we're positioned to begin exploring additional expansion opportunities. Vertical integration, expanding product distribution channels, and out-of-state manufacturing and processing are all opportunities we will aggressively develop and execute."
About Isodiol International Inc.
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=26509813#ru8WV5I4E3H8UWyZ.99
$LAGBF is one of the only companies in the Sector that is Profitable
We have developed product lines and brands which will generate revenues and profitability and now we're positioned to begin exploring additional expansion opportunities. Vertical integration, expanding product distribution channels, and out-of-state manufacturing and processing are all opportunities we will aggressively develop and execute."
ISODIOL INTERNATIONAL INC. ANNOUNCES UNAUDITED QUARTERLY PROFIT OF ISO INTERNATIONAL LLC
Isodiol International Inc. has released the operational numbers of its wholly owned subsidiary for the period from April 1, 2017, to June 30, 2017. ISO International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of $4,919,693.
Marcos Agramont, chief executive officer of Isodiol, stated: "Demonstrating Q1 profitability is a major milestone for our company and our investors. The cannabis industry on a whole will be legitimized by demonstrating successful commercialization and operating in an environment which promotes the cannabis movement. We have developed product lines and brands which will generate revenues and profitability and now we're positioned to begin exploring additional expansion opportunities. Vertical integration, expanding product distribution channels, and out-of-state manufacturing and processing are all opportunities we will aggressively develop and execute."
About Isodiol International Inc.
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=26509813#ru8WV5I4E3H8UWyZ.99
Now onto our next pick. The marijuana industry has been lightning hot upon expectations of favorable government rulings for recreational use and increased open-mindedness over cannabis-based medicinal uses. The issue with a lightning hot industry is that the major players in that industry tend to trade at quite aggressive valuations. There may be one exception to that.
Laguna Blends (LAGBF) has recently gone on an acquisition spree. It has changed its name to Isodiol International to reflect its largest acquisition. This stock is listed on the OTC and we rarely pick OTC stocks. But you really don't have much of a choice when it comes to weed companies. Isodiol trades frequently on the Canadian Stock Exchange under the symbol ISOL. So it's not quite like the typical OTC stock. LAGBF closed at 18.74 US cents on July 21 and ISOL at 23 CAD cents. With 173 million shares outstanding, Isodiol has a US market cap of $32 million and $40 million Canadian.
What makes ISOL/LAGBF stand out as an OTC company other than the fact that it is dual-listed is that it can claim that is is EBITDA positive:
While these numbers are unaudited, $12 million in revenue and $1.6 million in Adjusted EBITDA makes it sound like ISOL is a steal compared to its peers with a trailing revenue multiple of 2.7x.
Furthermore, the consolidated company "recorded sales of $1,843,173 CAD for the thirty-day period ended June 30, 2017. Total quarterly sales were $4,919,693 CAD for the period April 1st to June 30th, 2017" according to a press release on July 11. If sales are $5 million CAD per quarter, ISOL is trading at a 2x revenue multiple.
Contrast this to Canopy Growth Corporation (TWMJF) (WEED.to) which has a market cap of $1.37 CAD billion. Revenue was $14.7 million in its last reported quarter and $40 million for the year. Canopy's trailing revenue multiple is 34x while Q4 equates to a $60 million annualized run-rate or a revenue multiple of over 22x. Canopy is growing very quickly, but so ISOL so it's difficult to imagine that ISOL is over ten times undervalued compared to Canopy. Especially in light that the two companies have recently announced a distribution deal:
$LAGBF
Isodiol enters licensing deal with Canopy Growth
Isodiol International's June sales at $1.84-million
2017-07-11 10:18 ET - News Release
Mr. Marcos Agramont reports
Isodiol International Inc. has released its unaudited consolidated sales figures of $1,843,173 for the 30-day period ended June 30, 2017. The company recorded sales of $1,843,173 for the 30-day period ended June 30, 2017. Total quarterly sales were $4,919,693 for the period April 1 to June 30, 2017.
2017-07-20 02:09 ET - News Release
Also News Release (C-WEED) Canopy Growth Corp
Mr. Marcos Agramont of Isodiol reports
ISODIOL INTERNATIONAL INC. SIGNS DEFINITIVE LICENSING AGREEMENT WITH CANOPY GROWTH CORPORATION FOR CANADIAN AND INTERNATIONAL DISTRIBUTION
Isodiol International Inc. has signed a licensing agreement with Canopy Growth Corp.
Canopy Growth is the world's premier cannabis company that operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. Under this licensing agreement, Canopy Growth will have the right to manufacture and distribute the company's Pot-O-Coffee and Pot-O-Tea branded marijuana-infused single-serve K-Cup products in Canada and certain other markets internationally as federal regulations allow. Licensed products include caffeinated and decaffinated product lines, as well as Isodiol's single-serve Pot-O-Coco. In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the Pot-O brand products in any territory outside of the United States, Mexico and Puerto Rico.
"This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world," said Marcos Agramont, chief executive officer, Isodiol.
"We will continue to develop our Pot-O-Coffee product lines with ready-to-drink and cold-brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence," stated Isodiol's Mr. Agramont.
The availability of the various licensed products in Canada and elsewhere will differ depending on applicable laws and regulation. While Canadian law does not yet permit the manufacture and sale of marijuana-infused products, the company anticipates that such products will be permitted in the near future. Furthermore, currently proposed regulations, which would permit the sale of infused products, would not allow such products to contain both marijuana and caffeine. As such, the specific product offerings in Canada and elsewhere may be limited. The company will provide additional updates as regulations are adopted and as product rollout plans are developed.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade cannabis compounds and the industry leader in the manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for hemp-derived cannabidiol (CBD), including 99 per cent pure crystalline isolate, microencapsulation, and nanotechnology for the highest-quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries, and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
$LAGBF
Isodiol enters licensing deal with Canopy Growth
Isodiol International's June sales at $1.84-million
2017-07-11 10:18 ET - News Release
Mr. Marcos Agramont reports
Isodiol International Inc. has released its unaudited consolidated sales figures of $1,843,173 for the 30-day period ended June 30, 2017. The company recorded sales of $1,843,173 for the 30-day period ended June 30, 2017. Total quarterly sales were $4,919,693 for the period April 1 to June 30, 2017.
2017-07-20 02:09 ET - News Release
Also News Release (C-WEED) Canopy Growth Corp
Mr. Marcos Agramont of Isodiol reports
ISODIOL INTERNATIONAL INC. SIGNS DEFINITIVE LICENSING AGREEMENT WITH CANOPY GROWTH CORPORATION FOR CANADIAN AND INTERNATIONAL DISTRIBUTION
Isodiol International Inc. has signed a licensing agreement with Canopy Growth Corp.
Canopy Growth is the world's premier cannabis company that operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. Under this licensing agreement, Canopy Growth will have the right to manufacture and distribute the company's Pot-O-Coffee and Pot-O-Tea branded marijuana-infused single-serve K-Cup products in Canada and certain other markets internationally as federal regulations allow. Licensed products include caffeinated and decaffinated product lines, as well as Isodiol's single-serve Pot-O-Coco. In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the Pot-O brand products in any territory outside of the United States, Mexico and Puerto Rico.
"This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world," said Marcos Agramont, chief executive officer, Isodiol.
"We will continue to develop our Pot-O-Coffee product lines with ready-to-drink and cold-brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence," stated Isodiol's Mr. Agramont.
The availability of the various licensed products in Canada and elsewhere will differ depending on applicable laws and regulation. While Canadian law does not yet permit the manufacture and sale of marijuana-infused products, the company anticipates that such products will be permitted in the near future. Furthermore, currently proposed regulations, which would permit the sale of infused products, would not allow such products to contain both marijuana and caffeine. As such, the specific product offerings in Canada and elsewhere may be limited. The company will provide additional updates as regulations are adopted and as product rollout plans are developed.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade cannabis compounds and the industry leader in the manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for hemp-derived cannabidiol (CBD), including 99 per cent pure crystalline isolate, microencapsulation, and nanotechnology for the highest-quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries, and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.